Is all free time above the minimum inhibitory concentration the same:: implications for β-lactam in vivo modelling

被引:13
作者
DeRyke, C. Andrew
Nicolau, David P.
机构
[1] Hartford Hosp, Ctr Antiinfect Res & Dev, Hartford, CT 06102 USA
[2] Hartford Hosp, Div Infect Dis, Hartford, CT 06102 USA
关键词
pharmacokinetics/pharmacodynamics; in vivo efficacy; beta-lactams; ertapenem;
D O I
10.1016/j.ijantimicag.2006.10.006
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Previously, ertapenem 50 mg/kg every 6 h given subcutaneously to mice achieved a similar 24-h cumulative free time above the minimum inhibitory concentration (fT > MIC) to 1g every 24h in humans. However, this simplified regimen (SR) does not provide a superimposable concentration-time profile to that observed in humans, thus allowing concentrations to fluctuate above and below the minimum inhibitory concentration (MIC) throughout the 24-h period. Herein, we compared a complex regimen (CR; 9 various mglkg doses over 24 h) providing a near superimposable concentration-time profile with the SR to determine implications on bacterial kill against eight extended-spectrum beta-lactamase (ESBL)-producing isolates over a wide MIC range. The CR resulted in a similar ( +/- 5%) 24-h cumulative fT > MIC to ertapenem 1 g every 24 h in humans over an MIC range of 0.032 mg/L to 16 mg/L. Similar bacterial kill was observed with both regimens against all eight ESBL-producing isolates examined. In mouse models, it appears that the 24-h cumulativefr > MIC and not the distribution of theft > MIC over 24 h drives efficacy. (c) 2006 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:341 / 343
页数:3
相关论文
共 7 条
[1]  
Clinical and Laboratory Standards Institute, 2005, M100S15 CLSI
[2]   Prevention of resistance: A goal for dose selection for antimicrobial agents [J].
Drusano, GL .
CLINICAL INFECTIOUS DISEASES, 2003, 36 :S42-S50
[3]   Pharmacokinetics of total and unbound ertapenem in healthy elderly subjects [J].
Musson, DG ;
Majumdar, A ;
Holland, S ;
Birk, K ;
Xi, L ;
Mistry, G ;
Sciberras, D ;
Muckow, J ;
Deutsch, P ;
Rogers, JD .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2004, 48 (02) :521-524
[4]   Pharmacokinetics and pharmacodynamics of ertapenem: an overview for clinicians [J].
Nix, DE ;
Majumdar, AK ;
DiNubile, MJ .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2004, 53 :23-28
[5]   Comparative antimicrobial potency of meropenem tested against gram-negative bacilli: Report from the MYSTIC surveillance program in the United States (2004) [J].
Rhomberg, PR ;
Fritsche, TR ;
Sader, HS ;
Jones, RN .
JOURNAL OF CHEMOTHERAPY, 2005, 17 (05) :459-469
[6]  
Rolinson G N, 1980, Infection, VSuppl 1, P30
[7]   Pharmacodynamic assessment of ertapenem (MK-0826) against Streptococcus pneumoniae in a murine neutropenic thigh infection model [J].
Xuan, DW ;
Banevicius, M ;
Capitano, B ;
Kim, MK ;
Nightingale, C ;
Nicolau, D .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2002, 46 (09) :2990-2995